European Medicines Agency announces NexoBrid shortage for burn treatment.

The European Medicines Agency has reported a current shortage of NexoBrid, a critical medication for severe burn treatment, across several EU/EEA countries. This disruption, anticipated to continue until June 2026, stems from a sterility test issue identified in late 2025, which led to a temporary halt in distribution. Healthcare providers are advised to use alternative standard wound care methods for patients during this period.

Context

NexoBrid is used in the treatment of severe burns, facilitating the removal of dead tissue and promoting healing. The European Medicines Agency identified a sterility test issue in late 2025, which has led to a halt in its distribution. This shortage affects multiple countries within the EU and EEA, raising concerns about patient care.

Why it matters

The shortage of NexoBrid is significant as it is a vital treatment for patients with severe burns, impacting their recovery and quality of life. Without this medication, healthcare providers may struggle to deliver optimal care, potentially leading to increased complications. The situation highlights vulnerabilities in the supply chain for essential medical products.

Implications

Patients requiring severe burn treatment may face delays in recovery or suboptimal care due to the lack of NexoBrid. Healthcare systems may need to allocate additional resources to manage the increased demand for alternative treatments. This shortage may also prompt discussions about the reliability of pharmaceutical supply chains and the need for contingency planning.

What to watch

Healthcare providers are currently advised to implement alternative wound care methods, which may vary in effectiveness compared to NexoBrid. Monitoring the situation will be crucial as the shortage is expected to persist until June 2026. Updates from the European Medicines Agency regarding the resolution of the sterility issue will be important for future planning.